HGH Fragment 176-191 vs Retatrutide
Moderate Research vs Extensively Studied
monitor Mechanism-based · 47% Both HGH Fragment 176-191 and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
HGH Fragment 176-191 Retatrutide
Weight 1,817.1 Da 4,731.33 Da
Half-life 15-20 minutes ~6 days
Chain 16 amino acids 39 amino acids
Type hGH C-terminal fragment (176-191) Triple GLP-1/GIP/glucagon agonist
Key Benefits
HGH Fragment 176-191
01 Stimulates lipolysis without growth hormone side effects
02 Does not affect blood glucose or insulin sensitivity
03 Does not increase IGF-1 levels
04 Selectively targets fat metabolism
05 No impact on bone or organ growth
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
HGH Fragment 176-191
250-500mcg / Twice daily (fasted)
Fat loss - Standard 250mcg Twice daily (morning fasted + pre-bed)
Enhanced fat loss 500mcg Twice daily (morning fasted + pre-bed)
Conservative start 250mcg Once daily (morning, fasted)
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
HGH Fragment 176-191
Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
HGH Fragment 176-191 Retatrutide
Status Moderate Research Extensively Studied
References 4 studies 6 studies
Latest 2014 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.